Evonik and Vland Biotech Begin Joint Venture
Evonik Vland Biotech, a new joint venture between Evonik China and Shandong Vland Biotech, began operations on January 1, 2024. The venture aims to expand the market presence of their livestock probiotics in Greater China and develop new products. The official opening took place in Qingdao on March 14.
Evonik’s biotech platform is dedicated to creating biosolutions for healthier living. It innovates at the crossroads of chemistry, biotechnology, pharmacology, and data science. Skin applications, that enhance Evonik’s Care Solutions portfolio, exemplify these innovations.
“Vland and Evonik have been partnering for nearly 10 years. Through this relationship, we have created a strong foundation on which we can build”, said Johann-Caspar Gammelin, head of Evonik's Nutrition & Care division.
The joint venture is based at the Vland Biotech Park in Qingdao and uses Vland's production facilities in Huimin. Under the agreement with Vland, Evonik will also distribute the joint venture's portfolio outside the Greater China region. The joint venture complements Evonik's gut health portfolio with new components for formulated products and enables new solutions for gut health.
“Over the past decade, Vland and Evonik have been continuously broadened the scope of our cooperation and deepened our partnership,” said Arron Chen, Chairman and President of the Vland Group. “With the joint venture now fully operational, we are poised to capitalize on our expertise on the animal gut health and deliver effective and efficient products and solutions for our customers in China and worldwide.”
